The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Challenges in regards to adverse events when treating lung cancer with IO
Michel Obeid, MD, PhD, CHUV – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, talks on remaining challenges in regards to adverse events (AEs) when treating lung cancer with immunotherapy, including understanding the pathogenesis of AEs and finding an appropriate balance between maintaining an oncological response and risk of severe toxicity. This interview took place during the virtual European Lung Cancer Congress 2022.
